Polaris Rx Selected Again as Exclusive U.S. Distributor for FluMist Home for 2026–2027 Flu Season Polaris Rx, a provider of long-term care, specialty and infusion pharmacy solutions, has been selected for a second consecutive year as the exclusive U.S. distributor…
Corcept Therapeutics Names Justin Gunn President of Endocrinology Division as Sean Maduck Retires Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage biopharmaceutical company focused on developing and commercializing medicines that modulate the effects of the hormone cortisol, has announced a leadership…
NeuPath Health to Host 2026 Physician Forum Focused on Advances in Chronic and Musculoskeletal Pain Care NeuPath Health Inc. (TSXV: NPTH), a Canadian healthcare company operating one of the country’s largest networks of community-based, multidisciplinary medical facilities, will host its…
Pattern Bioscience Receives FDA Breakthrough Device Designation for Urine ID/AST Panel Pattern Bioscience, a company developing rapid diagnostic technologies for bacterial infections, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its investigational…
Roche Opens Innovation Center Boston to Expand Cardiovascular, Renal and Metabolism Research Roche (SIX: RO, ROP; OTCQX: RHHBY) has officially opened the Roche Genentech Innovation Center Boston, marking a significant expansion of the company’s research and development presence in the…
AbbVie Presents New VRAYLAR Data Highlighting Real-World Outcomes in Depression and Bipolar I Disorder AbbVie (NYSE: ABBV) has presented new data for VRAYLAR® (cariprazine) at Psych Congress 2026 in New Orleans, Louisiana, highlighting findings from prospective real-world observational studies in…
Lilly to Present New Cardiometabolic Data on Foundayo, Retatrutide and EloraTZP at EASD 2026 Eli Lilly and Company (NYSE: LLY), the manufacturer of Zepbound® (tirzepatide), Mounjaro® (tirzepatide) and Foundayo® (orforglipron), is set to present a broad range of new data…
MaaT Pharma Reports CHMP Maintains Negative Opinion on MaaT013 for Acute Graft-versus-Host Disease MaaT Pharma (Euronext: MAAT), a clinical-stage biotechnology company developing Microbiome Ecosystem Therapies™ (MET) designed to modulate the immune system and improve outcomes for patients with cancer, announced…
Paradromics Connexus BCI Enables First Participant to Communicate in Real Time Using Neural Signals Paradromics Inc., a neurotechnology company developing a high-data-rate brain-computer interface (BCI) platform aimed at restoring and enhancing human capabilities, has announced a major clinical milestone involving…
Lightcast Appoints Sarah Taylor, PhD, as Vice President of Science to Advance Envisia Single-Cell Analysis Platform Lightcast, a life science tools company focused on functional single-cell analysis, has appointed Sarah Taylor, PhD, as Vice President of Science, effective immediately. Taylor…
Family Heart Foundation Study Shows Machine Learning Model Can Help Identify ASCVD Patients at Higher Risk of Elevated Lp(a) The Family Heart Foundation, a leading research, education and advocacy organization focused on cardiovascular health, has announced the publication of a…
Roche Receives FDA Priority Review for Enspryng in MOGAD Following Positive Phase 3 Results Roche announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) seeking approval of Enspryng® (satralizumab)…